TY - JOUR
T1 - In vitro assessment of antimicrobial agents against toxoplasma gondii
AU - Harris, Carol
AU - Salgo, Miklos P.
AU - Tanowitz, Herbert B.
N1 - Funding Information:
Received for publication 13 April 1987, and in revised form 28 July 1987. This work was supported in part by grant AR020 from the New York State AIDS Institute; grant AI-12770 from the National Institute of Allergy and Infectious Diseases; grant HL-35882 from the National Heart, Lung, and Blood Institute; and a grant from Unimed (Somerville, New Jersey). We thank Adam Singer of Upjohn (Kalamazoo, Mich) for supplying clindamycin and its analogues, Unimed (Somerville, New Jersey) for their gift of spirogermanium, and Rh6ne-Poulenc Pharmaceuticals (Montreal, Quebec, Canada) for their gift of spiramycin. Please address requests for reprints to Dr. Murray Wittner, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461.
PY - 1988/1
Y1 - 1988/1
N2 - We have modified a method of quantitating growth of Toxoplasma organisms by measuring incorporation of [3H]uracil into Toxop/asma-mfeacd, differentiated L6E9 rat myocytes and have found that low-dose pyrimethamine (0.1 µg/ml) and sulfadiazine (25 µg/ml) are synergistic. Pyrimethamine at higher concentrations (0.5 and 1.0 µg/ml) inhibits uptake to the same degree as the low-dose pyrimethamine-sulfadiazine combination. Spiramycin was effective only at high concentrations (200 µ g/ml) and with prolonged incubation of >72 h. Clindamycin and several of its analogues, methotrexate and difluoromethylor- nithine, were all ineffective and showed no additive effect with either pyrimethamine or sulfadiazine. Spirogermanium, an experimental antineoplastic and antiprotozoan agent, was effective only at concentrations close to those toxic to the system. 5-Fluorouracil was effective even at 0.1 µ g/ml. At 0.01 (µ g/ml it was synergistic with pyrimethamine (0.1 xg/ml), and the combination was as effective as high-dose pyrimethamine (1.0 µg/ml).
AB - We have modified a method of quantitating growth of Toxoplasma organisms by measuring incorporation of [3H]uracil into Toxop/asma-mfeacd, differentiated L6E9 rat myocytes and have found that low-dose pyrimethamine (0.1 µg/ml) and sulfadiazine (25 µg/ml) are synergistic. Pyrimethamine at higher concentrations (0.5 and 1.0 µg/ml) inhibits uptake to the same degree as the low-dose pyrimethamine-sulfadiazine combination. Spiramycin was effective only at high concentrations (200 µ g/ml) and with prolonged incubation of >72 h. Clindamycin and several of its analogues, methotrexate and difluoromethylor- nithine, were all ineffective and showed no additive effect with either pyrimethamine or sulfadiazine. Spirogermanium, an experimental antineoplastic and antiprotozoan agent, was effective only at concentrations close to those toxic to the system. 5-Fluorouracil was effective even at 0.1 µ g/ml. At 0.01 (µ g/ml it was synergistic with pyrimethamine (0.1 xg/ml), and the combination was as effective as high-dose pyrimethamine (1.0 µg/ml).
UR - http://www.scopus.com/inward/record.url?scp=0023829936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023829936&partnerID=8YFLogxK
U2 - 10.1093/infdis/157.1.14
DO - 10.1093/infdis/157.1.14
M3 - Article
C2 - 3121760
AN - SCOPUS:0023829936
SN - 0022-1899
VL - 157
SP - 14
EP - 22
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -